Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 21, 2025

Overcoming Key Operational Challenges in Integrating Bispecific Therapies

Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.

Episodes in this series

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

3 experts are featured in this series.

EP. 2 Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

3 experts are featured in this series.

EP. 3 How Bispecific Antibodies Are Reshaping Cancer Care

3 experts are featured in this series.

EP. 4 Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

3 experts are featured in this series.

EP. 5 Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

3 experts are featured in this series.

EP. 6 Overcoming Key Operational Challenges in Integrating Bispecific Therapies

3 experts are featured in this series.

EP. 7 Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

3 experts are featured in this series.

EP. 8 Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

3 experts are featured in this series.

EP. 9 Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

3 experts are featured in this series.

EP. 10 Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

3 experts are featured in this series.

EP. 11 Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

3 experts are featured in this series.

EP. 12 Payer and Reimbursement Considerations for Bispecific Therapies

3 experts are featured in this series.

EP. 13 Emerging Therapeutic Areas for Bispecific Antibodies

3 experts are featured in this series.

EP. 14 Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

3 experts are featured in this series.

EP. 15 Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

What are the most common logistical challenges you encounter when implementing bispecific therapies?
What are the primary barriers that smaller community practices face in operationalizing bispecific antibody treatments?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Guidelines folder tab. | Image credit: @tashatuvango_AdobeStock.jpeg

NCCN Adds Pemivibart for COVID-19 Prevention in B-Cell Lymphomas

BySabrina McCrear

June 30th 2026

Immunoglobulins | Image credit: Dr_Microbe - stock.adobe.com

Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS

ByJulia Bonavitacola

June 30th 2026

Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH

ByNadege Gunn, MD

June 30th 2026

Experts featured in this series.

Beyond Brand vs. Generic: What Really Drives Treatment Decisions After Repeated Failures

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 30th 2026 | Updated: June 16th 2026

MASH in Focus: How Patient Awareness, Clinical Empowerment, and Research Have Transformed the Field

ByNadege Gunn, MD

June 30th 2026

Trending on AJMC

Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS

House Panel Advances Bills to Expand Veterans’ Health Care Access

House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden

The Oncology Care Model: A Decade of Transformation

JAK2 Therapies Show Promise, and a Catch, for MPN